Heart Disease News and Research

Latest Heart Disease News and Research

International consortium develops first-in-class adiponectin receptor agonist

A compound that mimics the effects of adiponectin, a beneficial protein that is produced by fat tissue in healthy weight individuals and may exhibit protective effects against cancer, cardiovascular disease, inflammatory conditions and insulin resistance has been developed by an international consortium lead by Dr. Eva Surmacz, Associate Professor in Biology (Adjunct) and director of the Obesity and Cancer Program at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University's College of Science and Technology.

16 Nov 2011

New health institute to combat chronic diseases across Maryland

Jay A. Perman, MD, President of the University of Maryland, and Joshua M. Sharfstein, MD, Secretary of the Maryland Department of Health and Mental Hygiene (DHMH), announced today the creation of the Institute for a Healthiest Maryland, a collaboration of support systems that will guide efforts to combat chronic diseases across Maryland.

16 Nov 2011

Evacetrapib drug may increase HDL-C and decrease LDL-C levels

Among patients with sub-optimal low-density lipoprotein cholesterol (LDL-C) or high-density lipoprotein cholesterol (HDL-C) levels, use of the drug evacetrapib alone or in combination with statin medications was associated with significant increases in HDL-C levels and decreases in LDL-C levels, according to a study appearing in the November 16 issue of JAMA, a theme issue on cardiovascular disease.

16 Nov 2011

Type 2 diabetics with low cholesterol may carry residual risk of cardiac events

LipoScience, Inc., an in-vitro diagnostic company advancing patient care in cardiovascular, metabolic and other diseases using an innovative and proprietary platform based on nuclear magnetic resonance (NMR) technology, recognizes a presentation of clinical data which suggests that type 2 diabetics with low non-HDL and low LDL cholesterol may carry residual risk of a cardiac event based on high LDL particle numbers.

16 Nov 2011

Scientists discover definitive role for brain in regulating loss of muscle mass

Patients with cancer, heart disease and other chronic illness struggle not only with complications inherent to their disease, they also experience an involuntary loss of weight and muscle mass triggered by the body's natural response to infection and inflammation. Increasing nutrition intake does not mitigate the process and there is no treatment.

16 Nov 2011

EPO-secreting engineered vessels could reverse anemia

Patients who rely on recombinant, protein-based drugs must often endure frequent injections, often several times a week, or intravenous therapy. Researchers at Children's Hospital Boston demonstrate the possibility that blood vessels, made from genetically engineered cells, could secrete the drug on demand directly into the bloodstream.

15 Nov 2011

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it will present new data from its ALN-TTR program at the VIIIth International Symposium on Familial Amyloidotic Polyneuropathy being held in Kumamoto, Japan from November 20-22, 2011.

15 Nov 2011

Multifaceted quality initiative can reduce adverse obstetric outcomes

A new study published in the Journal for Healthcare Quality reveals that a multifaceted quality initiative can significantly reduce adverse obstetric outcomes, thereby improving patient safety and enhancing staff and patient experiences.

15 Nov 2011

Children advised to get tested for cholesterol: Guidelines

According to latest medical guidelines announced Friday, all children aged 9 to 11 should have their cholesterol checked to help head off cardiovascular disease early. Overweight children and those who have other risks of Type 2 diabetes should be screened for diabetes every two years starting as early as 9, according to the panel.

15 Nov 2011

Xarelto (rivaroxaban) shows success as blood thinner in acute coronary syndrome

A new anti-blood clotting drug – Xarelto (rivaroxaban) has shown clinical success. It may help people with “acute coronary syndrome” lower their risk of death, subsequent heart attack or stroke, a new study finds. Acute coronary syndrome is term that includes people with angina or prior history of heart attack.

15 Nov 2011

Stem cell therapy remedies heart failure: Study

Heart failure may be sure cured using stem cell therapy claim researchers. In a breakthrough study 16 heart failure patients given stem cells taken from their own bodies showed dramatic and lasting improvement.

15 Nov 2011

King Faisal Specialty Hospital implements LUMEDX CVIS in its Heart Centre

LUMEDX Corporation, a provider of vendor-neutral, integrated cardiovascular information and imaging systems (CVIS), announced today that the King Faisal Specialty Hospital and Research Centre has deployed a comprehensive LUMEDX CVIS in its Heart Centre.

15 Nov 2011

Long-term AED therapy may increase risk of atherosclerosis in epilepsy patients

New research reveals that patients with epilepsy who were treated for extended periods with older generation antiepileptic drugs (AEDs) may be at increased risk for developing atherosclerosis, a common disorder known as hardening of the arteries.

15 Nov 2011

Positive long-term data from Abbott's ABSORB drug eluting BVS trial on CAD

Abbott today announced positive long-term data from the two-stage ABSORB trial, which is evaluating the ABSORB drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease.

15 Nov 2011

Stem cell therapy within 2 or 3 weeks does not improve heart function after attack

A research network led by a Mayo Clinic physician found that stem cells obtained from bone marrow delivered two to three weeks after a person has a heart attack did not improve heart function.

15 Nov 2011

POZEN reports positive Phase 1 study results comparing PA32540 to clopidogrel for CVDs

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented positive results today from a Phase 1 study comparing a dose-timing strategy of PA32540 and clopidogrel spaced 10 hours apart as compared to synchronous administration of enteric-coated (EC) omeprazole (40 mg), enteric-coated aspirin (81 mg) and clopidogrel.

15 Nov 2011

Stem cell injections within two weeks may not help in post heart attack recovery

University Hospitals Case Medical Center researchers could still be close to giving heart attack patients a second chance-just not as they originally thought.

15 Nov 2011

Study identifies demographic and health related characteristics related to mobility limitation

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health and featured in a 2011 issue of the Journal of Gerontology, has identified demographic and health related characteristics that were related to mobility limitation.

15 Nov 2011

Delay in hypothermia, ROSC linked with poor post cardiac arrest neurologic outcomes

Delay in initiation of therapeutic hypothermia and delay in return of spontaneous circulation (ROSC), evidenced by a palpable pulse or a measurable blood pressure, were both associated with poor neurologic outcomes in post cardiac arrest patients, according to a study being presented Nov. 14 at the at the American Heart Association (AHA) scientific sessions in Orlando, Fla.

15 Nov 2011

Eliminating drug co-pays improves medication adherence in heart attack patients

The use of specific medications following a heart attack has been shown to reduce cardiovascular events and mortality, however; while highly effective, the rate of adherence to these medications is poor. Researchers from Brigham and Women's Hospital (BWH) evaluated whether eliminating co-payments for these medications would increase adherence and improve outcomes in patients who have had a heart attack.

15 Nov 2011